(redirected from Prevacid 24HR)
Also found in: Dictionary, Thesaurus.


a proton pump inhibitor used to inhibit gastric acid secretion for the treatment of duodenal or gastric ulcer, gastroesophageal reflux disease, or other conditions due to gastric hyperacidity; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Prevacid, Prevacid SoluTab, Prevacid 24HR, Zoton (UK)

Pharmacologic class: Gastric acid pump inhibitor

Therapeutic class: Antiulcer drug

Pregnancy risk category B


Inhibits activity of proton pump in gastric parietal cells, decreasing gastric acid production


Capsules (delayed-release): 15 mg, 30 mg

Granules for oral suspension (delayed-release, enteric-coated): 15 mg, 30 mg

Prevpac (combination product for Helicobacter pylori infection): daily pack containing two 30-mg lansoprazole capsules, four 500-mg amoxicillin capsules, and two 500-mg clarithromycin tablets

Prevacid NapraPAC 375 (combination product for reducing risk of ulcers from nonsteroidal anti-inflammatory drugs [NSAIDs]): weekly pack containing seven 15-mg Prevacid capsules and fourteen 375-mg Naprosyn tablets

Prevacid NapraPAC 500 (combination product for reducing risk of ulcers from NSAIDs): weekly pack containing seven 15-mg Prevacid capsules and fourteen 500-mg Naprosyn tablets

Prevacid SoluTab (delayed-release, orally disintegrating tablet): 15 mg, 30 mg

Indications and dosages

Active duodenal ulcer

Adults: 15 mg P.O. daily for 4 weeks

Maintenance of healed duodenal ulcer

Adults: 15 mg P.O. daily

H. pylori eradication, to reduce risk of duodenal ulcer recurrence

Adults: In triple therapy, 30 mg lansoprazole P.O., 1 g amoxicillin P.O., and 500 mg clarithromycin P.O. q 12 hours for 10 or 14 days. In dual therapy, 30 mg lansoprazole P.O. and 1 g amoxicillin P.O. q 8 hours for 14 days.

Benign gastric ulcer

Adults: 30 mg P.O. daily for up to 8 weeks

Gastric ulcer associated with NSAIDs

Adults: 30 mg P.O. once daily for up to 8 weeks

To reduce risk of NSAID-associated gastric ulcer

Adults: 15 mg P.O. daily for up to 12 weeks

Gastroesophageal reflux disease

Adults and children ages 12 to 17: 15 mg P.O. daily for up to 8 weeks

Children ages 1 to 11 weighing more than 30 kg (66 1b): 30 mg P.O. daily for up to 12 weeks

Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks

Erosive esophagitis

Adults and children ages 12 to 17: 30 mg P.O. daily for up to 8 weeks. Some patients may require 8 additional weeks.

Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks

Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks

To maintain healing of erosive esophagitis

Adults: 15 mg P.O. daily

Pathologic hypersecretory conditions (including Zollinger-Ellison syndrome)

Adults: Initially, 60 mg P.O. daily, to a maximum of 90 mg P.O. b.i.d. Divide daily dosages over 120 mg.

Frequent heartburn (two or more times a week)

Adults: 15 mg P.O. (delayed-release capsule) daily up to 14 days

Dosage adjustment

• Significant hepatic insufficiency


• Hypersensitivity to drug or its components


Use cautiously in:

• phenylketonuria (orally disintegrating tablets), severe hepatic impairment

• elderly patients

• pregnant or breastfeeding patients

• children younger than age 18.


• Give oral form before meals.

• If patient has difficulty swallowing delayed-release capsule, open it and sprinkle contents onto small amount of soft food, such as applesauce or pudding. Don't crush or let patient chew drug.

• When giving orally disintegrating tablet, place tablet on patient's tongue and let it disintegrate until particles can be swallowed.

• Know that orally disintegrating tablet contains phenylalanine.

• When giving oral suspension, empty packet contents into container with 2 tbsp water. Stir contents well, and have patient drink immediately. Don't give oral suspension through nasogastric (NG) tube.

• When injecting contents of delayed-release capsule through NG tube, open capsule and mix granules with 40 ml apple juice. Then rinse tube with additional apple juice to clear.

Adverse reactions

CNS: headache, confusion, anxiety, malaise, paresthesia, abnormal thinking, depression, dizziness, syncope, cerebrovascular accident

CV: chest pain, hypertension, hypotension, myocardial infarction, shock

EENT: visual field deficits, otitis media, tinnitus, epistaxis

GI: nausea, diarrhea, abdominal pain, cholelithiasis, ulcerative colitis, esophageal ulcer, hematemesis, stomatitis, dysphagia, GI hemorrhage

GU: renal calculi, erectile dysfunction, abnormal menses, breast tenderness, gynecomastia

Hematologic: anemia

Musculoskeletal: hip, wrist, spine fractures (with long-term daily use)

Respiratory: cough, bronchitis, asthma

Skin: urticaria, alopecia, acne, pruritus, photosensitivity


Drug-drug. Drugs requiring acidic pH (such as ampicillin esters, digoxin, iron salts, itraconazole, ketoconazole): decreased absorption of these drugs

Sucralfate: decreased lansoprazole absorption

Theophylline: increased theophylline clearance

Drug-food. Any food: decreased rate and extent of GI drug absorption

Drug-herbs. Male fern: inactivation of herb

St. John's wort: increased risk of photosensitivity

Patient monitoring

• Monitor for GI adverse reactions.

• Assess nutritional status and fluid balance to identify significant problems.

Patient teaching

• Instruct patient to take before meals.

• If patient has difficulty swallowing, tell him to open delayed-release capsule and sprinkle contents onto small amount of soft food (such as applesauce or pudding). Emphasize that he must not crush or chew drug.

• Tell patient to take orally disintegrating tablet by placing it on tongue and letting it disintegrate.

• Instruct patient to take oral suspension by emptying packet contents into container with 2 tbsp water. Tell him to stir contents well and drink immediately.

• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A drug of the proton pump inhibitor class, C16H14F3N3O2S, used to treat esophagitis caused by gastroesophageal reflux disease and other disorders associated with increased gastric acid secretion.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


Prevacid® Therapeutics A proton pump–H+/K+-ATPase inhibitor similar to omeprazole which, with antibiotics–eg, amoxicillin, clarithromycin, and/or metronidazole, is used to eradicate H pylori in Pts with peptic ulcers, erosive esophagitis Adverse effects Diarrhea Contraindications CAD, MI, ASHD
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A PROTON PUMP INHIBITOR drug. A brand name is Zoton.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
(+0.9%) Market Dollar sales Dollar sales LEADING BRANDS ** share (000) % change Private Label 40.4% $62,954 - 3.9% Prilosec OTC 16.1% 25,010 - 9.4% Zantac 150 6.8% 10,650 + 12.1% Prevacid 24HR 4.9% 7,564 - 7.3% Gas X 3.5% 5,488 + 0.9% Pepcid AC 3.2% 5,050 + 2.9% Tums 2.8% 4,327 - 13.8% Tums Ultra 2.3% 3,564 + 3.9% Pepcid Complete 2.2% 3,348 + 54.1% Zegerid OTC 1.9% 3,017 - 3.4% TOTAL UNIT SALES * 58 mil.
On the nonfood side, the top 10 pacesetter products were: Procter & Gamble Co.'s Crest 3D White ($154.1 million), Novartis Consumer Health Inc.'s Prevacid 24HR ($127 million), Teva Women's Health Inc.'s Plan B One-Step ($78.3 million), Watson Pharma Inc.'s Next Choice ($78 million), Kimberly-Clark Corp.'s Hug-gies Pull-Ups Learning Designs ($66.8 million), Unilever's Dove Men+Care ($54.2 million), P&G's Olay Professional Pro-X ($49.4 million), P&G's Scope Outlast/ Crest Extra White Plus Scope Outlast/Oral-B Advantage Plus Scope Outlast ($46.8 million), Unilever's Dove Body Wash with NutriumMoisture ($40.5 million) and McNEIL-PPC Inc.'s Lister-ine/Reach Total Care mouthwash ($39.8 million).
Drug Stores * Brand Manufacturer Dollar Sales Total Sales $149,669,700 Private Label 63,180,490 Prilosec OTC Procter & Gamble 25,308,030 Zantac 150 Boehringer Ingelheim 8,876,420 Prevacid 24HR Novartis Consumer Health 7,675,225 Gas-X Novartis Consumer Health 5,273,307 Pepcid AC Johnson & Johnson-Merck 4,786,785 Turns GIaxoSmithKline 4,243,102 Turns Ultra GIaxoSmithKline 3,515,024 LactaidFast Act McNeilConsumer Products 3,079,330 Zegerid OTC Merck 2,948,154 % Change Dollar % Change Brand vs.
A major factor in the expansion of the antacid tablets segment has been the conversion of former prescription products to over-the-counter status, the most recent of which is Prevacid 24HR (Novartis Consumer Healthcare).
The hottest current example is Novartis' Prevacid 24HR, which generated $33.6 million in sales during the 12 weeks ended June 13 to move into second place behind Procter & Gamble Co.'s Prilosec, according to SymphonyIRI Group Inc.
ANTACID TABLETS Leading brands Dollar sales in drug stores (000) DOLLAR SALES Prilosec OTC $135,013 Prevacid 24HR 64,650 Total* Turns 40,916 $1.3 bill.